Shuwen Expands Executive Team Ahead of Continued Growth

Deqing, China, May 11, 2017 – Shuwen Biotech Co. Ltd. announces today that Dr. Vafa Amirkia and Ms. Ada Yuan have joined Shuwen as Director of Corporate Strategy and Business Development and Medical Director respectively.

Dr. Amirkia is responsible for shaping Shuwen’s commercial strategy and forging strategic alliances to drive Shuwen’s sustainable long-term growth globally. Dr. Amirkia holds over 10 years of commercial and regulatory strategy experience specifically focusing on the biotechnology and pharmaceutical industries in China. Dr. Amirkia received his Ph.D. in drug development and pharmacology from University College London (UCL) and B.S. in Physiology and Chinese from the University of Washington. Dr. Amirkia has resided in China for 10 years and holds full proficiency in English, Mandarin, and Persian.

Ms. Yuan is responsible for the Medical Department at Shuwen, focusing on IVD pre-clinical and clinical development and providing scientific support to the Marketing and Sales. Prior to Shuwen, Ms. Yuan has over fourteen years of experience in pharmaceutical industry with an expertise in the field of oncology. Ms. Yuan received her M.S. (Med.) in hematology from Fudan University, B.S. (Med.) in clinical medicine from Shandong University in China.

“We are very pleased to have Vafa and Ada join us as we expand continue to grow our domestic and global footprint and strengthen our technical expertise in the market” stated Jay Z. Zhang, Chairman and CEO of Shuwen Biotech. “Vafa’s ability to navigate the complex commercial environment in China and proven track-record is invaluable to helping Shuwen transform towards the future. Ada’s technical expertise will also surely prove highly valuable to Shuwen’s expanding sales reach in the hospital sector in China.”

About Shuwen Biotech Co., Ltd.

Based in China, Shuwen Biotech is a diagnostic company providing China’s physicians and their patients with the most innovative diagnostic products and services to meet the growing need for improved prediction, prevention, diagnosis, prognosis, and treatment of diseases. The company is engaged in licensing, developing, marketing and distributing innovative diagnostic products and services for disease diagnosis and personalized medicine. Shuwen has capabilities for in vitro diagnostic kit (IVD) and laboratory-developed tests (LDT). Visit www.shuwenbiotech.com for more information.